An Open-label Study of Nelotanserin in Patients With Lewy Body Dementia Who Have Frequent Visual Hallucinations or REM Sleep Behavior Disorder
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Nelotanserin (Primary)
- Indications Lewy body disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Axovant Sciences
- 13 Feb 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.
- 13 Feb 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.
- 07 Aug 2017 According to a Axovant media release, the company anticipates top-line results in the first quarter 2018.